NASDAQInformation TechnologySoftware - ApplicationSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for AUUD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Progress in AI capabilities development | A primary condition in AUDDIA INC's published investment case. The stated target is Significant progress toward first AI datacenter deployment by end 2026. | Intact | No meaningful AI deployment progress by end 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, high-risk growth and merger-execution story, not a proven durable compounder. The thesis is in a watch state: management is advancing the merger and AI priorities, but the deal remains incomplete and the business is loss-making.
The valuation model has low confidence and shows AUUD trading at a large premium to peers, with optionality, or the chance that future opportunities add value, as the main driver. The evidence does not specify what investors already assume about those opportunities, so the expectations gap is unclear; low fragility signals do not remove the underlying business risks.
Near term, weak results, a record of recent misses, and an elevated risk of another miss point to continued earnings pressure. Over the multi-year view, progress depends on closing the Thramann merger, developing LT350, Influence Healthcare, and Voyex, and securing enough cash to fund milestones; recent acquisition announcements show activity, but not proof of lasting financial improvement.
A favorable scenario would require the merger to close and the AI-focused subsidiaries to advance, while steadier technology-sector conditions or lower interest rates could provide support. The thesis would weaken if growth slows materially, financing proves inadequate, or execution remains unsettled; the merger vote has already been adjourned and rescheduled.
For the next 1 to 3 years, AUUD remains a high-risk, loss-making business with significant execution and funding questions, despite active merger and AI plans. The long-term thesis hinges on those plans becoming measurable business progress. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in AUDDIA INC's published investment case. The stated target is Manage capital raises without excessive dilution through 2026. |
| Under Pressure |
| Excessive dilution or poor capital use harming shareholder value |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Improvement in earnings toward profitability | A primary condition in AUDDIA INC's published investment case. The stated target is Reduce EPS losses significantly toward breakeven by FY27. | Broken | EPS remains below -$1.49 or worsens in FY27 | Diluted EPS: $-0.71 per share FY2026-Q2; GAAP. Published target: Reduce EPS losses significantly toward breakeven by FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 2026-0.71 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Successful M&A to enhance capabilities and market position | The company actively pursues M&A to strengthen its market position. | Improving | No material M&A activity by end 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.